 |
|
Nicotine Inhaler and Nicotine Patch as a Combination Therapy for Smoking Cessation
A Randomized, Double-blind, Placebo-Controlled Trial
Abraham Bohadana, MD;
Fredrik Nilsson, MSc;
Thomas Rasmussen, MSc;
Yves Martinet, MD, PhD
Arch Intern Med. 2000;160:3128-3134.
Background Nicotine replacement therapy is an effective treatment for nicotine-dependent smokers. However, cessation rates are modest, and preliminary studies suggest that combination therapy may be superior. We compared the efficacy of the nicotine inhaler plus nicotine patch vs nicotine inhaler plus placebo patch for smoking cessation.
Methods A double-blind, randomized, placebo-controlled trial was conducted in 400 subjects who had smoked 10 or more cigarettes per day for 3 years or longer. Group 1 (n = 200) received the nicotine inhaler plus nicotine patch (delivering 15 mg of nicotine per 16 hours) for 6 weeks, then inhaler plus placebo patch for 6 weeks, then inhaler alone for 14 weeks. Group 2 (n = 200) received the nicotine inhaler plus placebo patch for 12 weeks, then inhaler for 14 weeks. Inhaler was used at a rate of 6 to 12 cartridges per day ad libitum for 3 months and then tapered off. Main outcome measures were complete abstinence (self-reported) and expired carbon dioxide concentration less than 10 ppm.
Results Group 1 vs group 2 complete abstinence rates were 60.5% and 47.5% at 6 weeks (P = .009), 42.0% and 31.0% at 12 weeks (P = .02), 25.0% and 22.5% at 6 months (P = .56), and 19.5% and 14.0% at 12 months (P = .14). One-year survival analysis showed a significant association between abstinence and treatment with nicotine inhaler plus nicotine patch (P = .04). Mean nicotine substitution at week 6 was 60.1% (group 1) and 24.6% (group 2) (P<.001). At 12 months, the frequency of respiratory symptoms in abstinent subjects fell significantly and lung function showed a trend toward improvement. The most common adverse events were throat irritation (inhaler) and itching (patch).
Conclusions Treatment with the nicotine inhaler plus nicotine patch resulted in significantly higher cessation rates than inhaler plus placebo patch.
From the Institut National de la Santé et de la Récherche Médicale Unité 420, Epidémiologie Santé Travail, Vandoeuvre, France (Dr Bohadana); Pharmacia & Upjohn Consumer Healthcare, Clinical Research, Helsingborg, Sweden (Messrs Nilsson and Rasmussen); and Fédération de Pneumologie, Centre Hospitalier Universitaire de Nancy-Brabois, Vandoeuvre-lès-Nancy, France (Drs Bohadana and Martinet).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
State of the Art Reviews: Smoking Cessation: A Review of Treatment Considerations
Sullivan et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:201-213.
ABSTRACT
Systematic Review: Smoking Cessation Intervention Strategies for Adults and Adults in Special Populations
Ranney et al.
ANN INTERN MED 2006;145:845-856.
ABSTRACT
| FULL TEXT
Tobacco dependence treatment: time to change the paradigm.
Sachs
Chest 2006;129:836-839.
FULL TEXT
"Tobacco Free With FDNY": The New York City Fire Department World Trade Center Tobacco Cessation Study.
Bars et al.
Chest 2006;129:979-987.
ABSTRACT
| FULL TEXT
Detecting Airflow Obstruction in Smoking Cessation Trials: A Rationale for Routine Spirometry
Bohadana et al.
Chest 2005;128:1252-1257.
ABSTRACT
| FULL TEXT
The Dirty Dozen: 12 Myths That Undermine Tobacco Control
Frieden and Blakeman
Am. J. Public Health 2005;95:1500-1505.
ABSTRACT
| FULL TEXT
Chronic obstructive pulmonary disease * 8: Non-pharmacological management of COPD
Morgan and Britton
Thorax 2003;58:453-457.
ABSTRACT
| FULL TEXT
Treatment of Tobacco Use and Dependence
Rigotti
NEJM 2002;346:506-512.
FULL TEXT
Other Articles Noted
Evid. Based Nurs. 2001;4:E1-11.
FULL TEXT
Other articles noted
Evid. Based Ment. Health 2001;4:36-36.
FULL TEXT
|
